J&J and Sanofi-part­nered oral de­liv­ery biotech rais­es $26M on lat­est of­fer­ing

Ac­cord­ing to an SEC fil­ing Tues­day, i2o Ther­a­peu­tics raised $26 mil­lion in a pri­vate stock of­fer­ing.

The Har­vard spin­out start­ed out in April 2020 with $4 mil­lion in seed fund­ing led by Sanofi Ven­tures and JDRF T1D Fund. Then, less than a year lat­er, Sanofi re­turned for a part­ner­ship with i2o, cen­ter­ing around the oral de­liv­ery of nanobody-based drugs.

And ear­li­er this year, i2o inked an­oth­er big phar­ma pact — this time with J&J’s Janssen. But in­stead of nanobody-based drugs, the J&J col­lab­o­ra­tion fo­cus­es on the oral de­liv­ery of macro­mol­e­cules.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER